2026
article
OpenAlex
Nobuaki Matsubara, Teresa Alonso Gordoa, Victor Moreno, Adanma Ayanambakkam et autres
e17043 Background: M is a potent and selective inhibitor of enhancer of zeste homolog 2. M 1250 mg twice daily (BID) on an empty stomach + E + androgen deprivation therapy showed improved outcomes vs E alone in pts with mCRPC, with …
jp, es, us, cn
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Rana R. McKay, Kai‐Jie Yu, Teresa Alonso Gordoa, Johann S. De Bono et autres
TPS5139 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease with high morbidity and a median overall survival of approximately two years. Human kallikrein 2 (KLK2) is highly and specifically expressed in normal and malignant prostate tissue, including late stage mCRPC. …
us, tw, es, gb, de, au, ca, fr, cn
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Pau Mascaró-Baselga, José Miguel Rodellar Sanz, Tiago Nunes, J. Hernando et autres
BACKGROUND: Anaplastic thyroid cancer (ATC) is an extremely rare cancer with very poor prognosis. Targeted therapies have improved outcomes in selected patients, but molecular testing is often difficult because of the aggressive course, rapid clinical deterioration, and long turnaround times. This study …
es
(code pays fourni par la source)